Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.35 | N/A | -5.80% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.35 | N/A | -5.80% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a cautious optimism about their future projects. They acknowledged the challenges but remain focused on their long-term goals.
Management highlighted ongoing progress in their clinical trials.
They emphasized their commitment to advancing their pipeline despite current losses.
Despite missing on EPS, Kodiak Sciences saw a positive stock reaction, rising 12.61%. This increase may reflect investor confidence in the company's ongoing clinical trials and future potential. The lack of revenue data and guidance indicates uncertainty, but management's comments suggest they are focused on long-term growth.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TERAWULF INC
May 15, 2023